A detailed history of Abel Hall, LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Abel Hall, LLC holds 11,416 shares of LYEL stock, worth $4,908. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,416
Holding current value
$4,908
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 06, 2025

BUY
$0.48 - $0.74 $5,479 - $8,447
11,416 New
11,416 $6.14 Million

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $107M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Abel Hall, LLC Portfolio

Follow Abel Hall, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abel Hall, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Abel Hall, LLC with notifications on news.